Immune Pharmaceuticals (NASDAQ:IMNP) is developing bertilimumab, a first-in-class fully human monoclonal antibody that targets eotaxin-1, a potent chemoattractant and activator of eosinophils. Immune is currently testing bertilimumab in a Phase 2 clinical trial for ulcerative colitis (UC) with plans to start a Phase 2 trial for bullous pemphigoid (BP) shortly. We believe there is a meaningful opportunity for Immune to position bertilimumab as a first-line treatment for BP due to the fact there is no cure and current treatment options have multiple, deleterious side effects. Below we give an overview of bertilimumab, BP, and the clinical development plans for the treatment for BP.
Immune is developing bertilimumab, a first-in-class fully human IgG4 monoclonal antibody targeted against
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|